Victoza is human glucagon-like peptide-1 (GLP-1) analogue that is similar to endogenous human GLP-1 and works by stimulating the beta cells to release insulin only when blood sugar levels are high.

Victoza has been proven to lower blood sugar levels, reduce body weight, lower systolic blood pressure, and shows improvements in measurements of beta cell function.

The company said Victoza has a low risk of hypoglycaemia and showed safety profile.

Novo Nordisk senior vice president and head Ron Christie said they believe the benefits associated with Victoza will help more people with type 2 diabetes in China achieve better control of their disease.